Role of a Modified Urothelium Immune Prognostic Index in Patients With Metastatic Urothelial Carcinoma Treated With Anti–PD-1/PD-L1–Based Therapy

Introduction: The use of antibodies against programmed death receptor-1 (PD-1) and its ligand (PD-L1) has improved survival in metastatic urothelial carcinoma (mUC) patients. However, reliable and convenient biomarkers of early responses and outcomes are still lacking. Materials and Methods: We retr...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Haifeng, An, Xin, Huang, Riqing, Li, Lu, Chu, Chengbiao, Yang, Wei, Qin, Zike, Liu, Zhuowei, Zhou, Fangjian, Xue, Cong, Shi, Yanxia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Molecular Biosciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8387676/
https://www.ncbi.nlm.nih.gov/pubmed/34458319
http://dx.doi.org/10.3389/fmolb.2021.621883

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8387676/
https://www.ncbi.nlm.nih.gov/pubmed/34458319
http://dx.doi.org/10.3389/fmolb.2021.621883

Ejemplares similares